Home » Posts tagged with » China
COVID-19 treatment : Cyclica, Institute of Materia Medica partner on drug repurposing for coronavirus

COVID-19 treatment : Cyclica, Institute of Materia Medica partner on drug repurposing for coronavirus

COVID-19 treatment : The Institute of Materia Medica, Chinese Academy of Medical Sciences has entered into a collaboration with Canadian biotech company Cyclica for discovering antiviral drug candidates for COVID-19 (novel coronavirus) and for exploring opportunities for designing multi-targeted antiviral compounds. According to the partners, new drug development efforts to tackle the prevailing pandemic of […]

ImmunoPrecise Antibodies launches vaccine development program for COVID-19

ImmunoPrecise Antibodies has launched a coronavirus vaccine development program to address the new coronavirus originating in Wuhan, China apart from developing coronavirus-neutralizing antibodies for addressing prophylactic and therapeutic measures to counter the virus and its associated disease, COVID-19. So far, COVID-19 has claimed the lives of nearly 1,875 people, while infecting more than 74,000 across […]

Continue reading …
Wuhan coronavirus : AirPHX non-thermal plasma technology to protect from deadly virus

AirPHX said that an independent testing lab has confirmed that its non-thermal plasma technology is highly effective in protecting people from potential exposure to the Wuhan coronavirus or novel coronavirus (2019-nCoV). The technology from airPHX can be scaled for the treatment of air and surfaces in large facilities like hospitals, hotels, airports, schools, and other […]

Continue reading …
Traveler brings Novel Coronavirus in US from Chinese city Wuhan

Wuhan Coronavirus cases in US : The deadly Novel Coronavirus (2019-nCoV infection) has made its way to the US owing to the return of a traveler from China, as confirmed by the Centers for Disease Control and Prevention (CDC). The first Novel Coronavirus case in US has been reported from Washington State after a patient […]

Continue reading …
Chinese pharma company CF PharmTech raises $90m for respiratory drugs

Chinese pharma company CF PharmTech has secured a $90 million Series E investment led by New Alliance Capital for accelerating the global development of respiratory drugs. The investment round saw participation from new investors such as CR-CP Life Science Fund, Finnova Capital, Xiangcheng Financial, GT Capital, Co-stone Asset Management, and Everest Venture Capital. Existing investors […]

Continue reading …
Genetron Health’s semiconductor-based NGS system gets Chinese approval

Genetron Health has been granted approval by China’s National Medical Products Administration (NMPA) for GENETRON S5, its semiconductor-based next-generation sequencing system (NGS system). With the approval, the Chinese precision oncology company can launch the new desktop medium-throughput NGS system for clinical applications. The NGS system has been developed by Genetron Health for the detection of […]

Continue reading …
Innovent Biologics begins phase 1 trial of IBI315 in solid malignancies

Innovent Biologics and Beijing Hanmi Pharmaceutical, a subsidiary of Hanmi Pharmaceutical, said that the first patient has been dosed in a phase 1 clinical trial in China for evaluating IBI315 for the treatment of advanced solid malignancies. IBI315, which has been co-developed by the companies, is a recombinant fully human bispecific antibody targeting programmed cell […]

Continue reading …
Gsport creates cohesive bandages for human and animal patients

Gsport, a Chinese sports medicine company claims to have created high-quality cohesive bandages for human and animal patients. The company, which manufactures therapeutic products in its Zhejiang facility, has expanded its business into the US. Its products range from cold bags, athletic tape, and kinesiology tape for athletic care. All the athletic care products are […]

Continue reading …
Chinese biopharma company Akeso raises $150m for antibody drug discovery

Akeso, a Chinese biopharma company engaged in antibody drug discovery and development in oncology and immunology therapeutic areas, has raised nearly $150 million through a Series D funding round. The investment in the clinical stage company was led by Loyal Valley Capital (LVC) and Sino Biopharmaceutical. The co-investors in the Series D round are healthcare […]

Continue reading …
Amgen to take 20.5% stake in Chinese biotech company BeiGene for $2.7bn

US biopharma company Amgen has signed an all-cash deal to acquire a 20.5% stake in Chinese biotech company BeiGene for about $2.7 billion, as per the latest pharma acquisition news. The Beijing-based BeiGene is a research-based, oncology-focused biotechnology company, which is engaged in developing molecularly targeted and immuno-oncology drug candidates for cancer treatment. The transaction […]

Continue reading …
Page 1 of 3123